NCT06235281View on ClinicalTrials.gov

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2029

Conditions
Mycosis Fungoides
Interventions
DRUG

Mogamulizumab-Kpkc

Participants will receive 8 total cycles of Mogamulizumab-Kpkc over approximately 224 days.

DEVICE

Phototherapy

Participants will begin receiving Phototherapy on day 56 and will continue until day 224. Participants with Complete response (CR) or Partial response (PR) to therapy at day 224 will remain on phototherapy maintenance.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors
All Listed Sponsors
collaborator

Kyowa Hakko Kirin Pharma, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT06235281 - Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) | Biotech Hunter | Biotech Hunter